Nationale kliniske anbefalinger om brug af lægemidler ved forebyggelse og behandling af covid-19

Published by Sundhedsstyrelsen on Apr 26, 2023

Disclaimer

Sundhedsstyrelsens nationale kliniske anbefalinger er systematisk udarbejdede udsagn med inddragelse af relevant sagkundskab. Nationale kliniske anbefalinger bruges af fagpersoner, når de skal træffe beslutninger om passende og god klinisk sundhedsfaglig ydelse i specifikke situationer. De nationale kliniske anbefalinger offentligt tilgængelige, således at borgere og patienter også kan orientere sig i anbefalingerne.
​Nationale kliniske anbefalinger klassificeres som faglig rådgivning, hvilket indebærer, at Sundhedsstyrelsen anbefaler relevante fagpersoner at følge anbefalingerne. De nationale kliniske anbefalinger er ikke juridisk bindende, og det vil altid være det faglige skøn i den konkrete kliniske situation, der er afgørende for beslutningen om passende og korrekt sundhedsfaglig ydelse. Der er ingen garanti for et succesfuldt behandlingsresultat, selvom sundhedspersoner følger anbefalingerne. I visse tilfælde kan en behandlingsmetode, som ikke er anbefalet være at foretrække, fordi den passer bedre til patientens situation. Sundhedspersoner skal generelt inddrage patienten, når de vælger behandling.

ISBN elektronisk udgave: 978-87-7014-506-0

Sponsors

Sundhedsstyrelsen

Contact

Abstract

Language

dk

PICOS

PICO 1.1

Population
Adults over 16 years with covid-19 who require oxygen
Intervention
Corticosteroids
Comparator
Standard care
Outcomes

PICO 1.1

Population
Adults over 16 years with moderate/serious COVID-19
Intervention
Therapeutic anticoagulants
Comparator
Prophylatic anticoagulants
Outcomes

PICO 1.1

Population
Adults over 16 years with covid-19
Intervention
Baricitinib
Comparator
Standard care
Outcomes

PICO 1.1

Population
Pregnant women over 16 years with moderate/serious covid-19 [adapted from general adult population]
Intervention
Therapeutic anticoagulants
Comparator
Prophylatic anticoagulants
Outcomes

PICO 1.1

Population
Adults over 16 years with covid-19
Intervention
Sarilumab
Comparator
Standard care
Outcomes

PICO 1.1

Population
Breastfeeding women over 16 years with moderate/serious covid-19 [adapted from general adult population]
Intervention
Therapeutic anticoagulants
Comparator
Prophylatic anticoagulants
Outcomes

PICO 1.1

Population
Adults over 16 years with covid-19
Intervention
Tocilizumab
Comparator
Standard care
Outcomes

PICO 1.1

Population
Children and adolescents under 16 years with mild or moderate covid-19 [adapted from general adult population]
Intervention
Remdesivir
Comparator
Standard care
Outcomes

PICO 1.1

Population
Children and adolescents below 16 years with moderate/serious covid-19 [adapted from general adult population]
Intervention
Therapeutic anticoagulants
Comparator
Prophylatic anticoagulants
Outcomes

PICO 1.1

Population
Breastfeeding women over 16 years with mild or moderate covid-19 [adapted from general adult population]
Intervention
Remdesivir
Comparator
Standard care
Outcomes

PICO 1.1

Population
Adults over 16 years with mild or moderate covid-19
Intervention
Evusheld
Comparator
Standard care
Outcomes

PICO 1.1

Population
Pregnant women over 16 years with mild or moderate covid-19 [adapted from general adult population]
Intervention
Remdesivir
Comparator
Standard care
Outcomes

PICO 1.1

Population
Pregnant women with covid-19 who require oxygen [adapted from general adult population]
Intervention
Corticosteroids
Comparator
Standard care
Outcomes

PICO 1.1

Population
Adults over 16 years with mild or moderate covid-19
Intervention
Sotrovimab
Comparator
Standard care
Outcomes

PICO 1.1

Population
Adults over 16 years with mild or moderate covid-19
Intervention
Remdesivir
Comparator
Standard care
Outcomes

PICO 1.1

Population
Children or adolescents below 16 years with covid-19 who require oxygen [adapted from general adult population]
Intervention
Corticosteroids
Comparator
Standard care
Outcomes

PICO 1.1

Population
Adults over 16 years with mild or moderate covid-19
Intervention
Casirivimab plus imdevimab
Comparator
Standard care
Outcomes

PICO 1.1

Population
Breastfeeding women with covid-19 who require oxygen [adapted from general adult population]
Intervention
Corticosteroids
Comparator
Standard care
Outcomes

PICO 1.2

Population
Children and adolescents below 16 years with moderate/serious covid-19 [adapted from general adult population]
Intervention
Intermediate anticoagulants
Comparator
Prophylactic anticoagulants
Outcomes

PICO 1.2

Population
Adults over 16 years with moderate/serious COVID-19
Intervention
Intermediate anticoagulants
Comparator
Prophylactic anticoagulants
Outcomes

PICO 1.2

Population
Breastfeeding women over 16 years with moderate/serious covid-19 [adapted from general adult population]
Intervention
Intermediate anticoagulants
Comparator
Prophylactic anticoagulants
Outcomes

PICO 1.2

Population
Pregnant women over 16 years with moderate/serious covid-19 [adapted from general adult population]
Intervention
Intermediate anticoagulants
Comparator
Prophylactic anticoagulants
Outcomes

PICO 2.1

Population
Adults over 16 years with covid-19 who do not require oxygen
Intervention
Corticosteroids
Comparator
Standard Care
Outcomes

PICO 2.1

Population
Adults over 16 years with critical COVID-19
Intervention
Therapeutic anticoagulants
Comparator
Prophylatic anticoagulants
Outcomes

PICO 2.1

Population
Pregnant women over 16 years with mild or moderate covid-19 [adapted from general adult population]
Intervention
Casirivimab plus imdevimab
Comparator
Standard care
Outcomes

PICO 2.1

Population
Pregnant women over 16 years with critical covid-19 [adapted from general adult population]
Intervention
Therapeutic anticoagulants
Comparator
Prophylatic anticoagulants
Outcomes

PICO 2.1

Population
Breastfeeding women over 16 years with critical COVID-19 [adapted from general adult population]
Intervention
Therapeutic anticoagulants
Comparator
Prophylatic anticoagulants
Outcomes

PICO 2.1

Population
Pregnant women over 16 years with mild or moderate covid-19 [adapted from general adult population]
Intervention
Sotrovimab
Comparator
Standard care
Outcomes

PICO 2.1

Population
Children and adolescents below 16 years with critical covid-19 [adapted from general adult population]
Intervention
Therapeutic anticoagulants
Comparator
Prophylatic anticoagulants
Outcomes

PICO 2.1

Population
Pregnant women over 16 years with mild or moderate covid-19 [adapted from general adult population]
Intervention
Evusheld
Comparator
Standard care
Outcomes

PICO 2.1

Population
Pregnant women with covid-19 [adapted from general adult population]
Intervention
Tocilizumab
Comparator
Standard care
Outcomes

PICO 2.1

Population
Adults over 16 years with serious covid-19
Intervention
Remdesivir
Comparator
Standard care
Outcomes

PICO 2.1

Population
Children or adolescents below 16 years with covid-19 who do not require oxygen [adapted from general adult population]
Intervention
Corticosteroids
Comparator
Standard care
Outcomes

PICO 2.1

Population
Pregnant women with covid-19 who require oxygen, no ventilation [adapted from general adult population]
Intervention
Remdesivir
Comparator
Standard care
Outcomes

PICO 2.1

Population
Pregnant women with covid-19 who require oxygen, no ventilation [adapted from general adult population]
Intervention
Remdesivir
Comparator
Standard care
Outcomes

PICO 2.1

Population
Breastfeeding women with covid-19 who do not require oxygen [adapted from general adult population]
Intervention
Corticosteroids
Comparator
Standard care
Outcomes

PICO 2.1

Population
Children and adolescents with covid-19 who require oxygen, no ventilation [adapted from general adult population]
Intervention
Remdesivir
Comparator
Standard care
Outcomes

PICO 2.1

Population
Pregnant women with covid-19 who do not require oxygen [adapted from general adult population]
Intervention
Corticosteroids
Comparator
Standard care
Outcomes

PICO 2.1

Population
Pregnant women with covid-19 [adapted from general adult population]
Intervention
Sarilumab
Comparator
Standard care
Outcomes

PICO 2.1

Population
Pregnant women with covid-19 [adapted from general adult population]
Intervention
Baricitinib
Comparator
Standard care
Outcomes

PICO 2.2

Population
Pregnant women over 16 years with critical covid-19 [adapted from general adult population]
Intervention
Intermediate anticoagulants
Comparator
Prophylactic anticoagulants
Outcomes

PICO 2.2

Population
Breastfeeding women over 16 years with critical COVID-19 [adapted from general adult population]
Intervention
Intermediate anticoagulants
Comparator
Prophylactic anticoagulants
Outcomes

PICO 2.2

Population
Adults over 16 years with critical COVID-19
Intervention
Intermediate anticoagulants
Comparator
Prophylactic anticoagulants
Outcomes

PICO 2.2

Population
Children and adolescents below 16 years with critical covid-19 [adapted from general adult population]
Intervention
Intermediate anticoagulants
Comparator
Prophylactic anticoagulants
Outcomes

PICO 3.1

Population
Breastfeeding women over 16 years with mild or moderate covid-19 [adapted from general adult population]
Intervention
Casirivimab plus imdevimab
Comparator
Standard care
Outcomes

PICO 3.1

Population
Børn og unge med alvorlig/kritisk covid-19
Intervention
Højdosis systemisk glukokortikoid
Comparator
Standard (lav) dosis systemisk glukokortikoid
Outcomes

PICO 3.1

Population
Voksne med alvorlig/kritisk covid-19
Intervention
Højdosis systemisk glukokortikoid
Comparator
Standard (lav) dosis systemisk glukokortikoid
Outcomes

PICO 3.1

Population
Gravide med alvorlig/kritisk covid-19
Intervention
Højdosis systemisk glukokortikoid
Comparator
Standard (lav) dosis systemisk glukokortikoid
Outcomes

PICO 3.1

Population
Breastfeeding women over 16 years with mild or moderate covid-19 [adapted from general adult population]
Intervention
Sotrovimab
Comparator
Standard care
Outcomes

PICO 3.1

Population
Ammende med alvorlig/kritisk covid-19
Intervention
Højdosis systemisk glukokortikoid
Comparator
Standard (lav) dosis systemisk glukokortikoid
Outcomes

PICO 3.1

Population
Breastfeeding women with covid-19 [adapted from general adult population]
Intervention
Baricitinib
Comparator
Standard care
Outcomes

PICO 3.1

Population
Breastfeeding women over 16 years with mild or moderate covid-19 [adapted from general adult population]
Intervention
Evusheld
Comparator
Standard care
Outcomes

PICO 3.1

Population
Adults over 16 years with covid-19 who require ventilation
Intervention
Remdesivir
Comparator
Standard care
Outcomes

PICO 3.1

Population
Pregnant women with covid-19 who require ventilation [adapted from general adult population]
Intervention
Remdesivir
Comparator
Standard care
Outcomes

PICO 3.1

Population
Breastfeeding women with covid-19 who require ventilation [adapted from general adult population]
Intervention
Remdesivir
Comparator
Standard care
Outcomes

PICO 3.1

Population
Children and adolescents with severe covid-19 who require ventilation [adapted from general adult population]
Intervention
Remdesivir
Comparator
Standard care
Outcomes

PICO 3.1

Population
Breastfeeding women with covid-19 [adapted from general adult population]
Intervention
Tocilizumab
Comparator
Standard care
Outcomes

PICO 3.1

Population
Breastfeeding women with covid-19 [adapted from general adult population]
Intervention
Sarilumab
Comparator
Standard care
Outcomes

PICO 4.1

Population
Children and adolescents under 16 years with mild or moderate covid-19 [adapted from general adult population]
Intervention
Evusheld
Comparator
Standard care
Outcomes

PICO 4.1

Population
Children and adolescents under 16 years with mild or moderate covid-19 [adapted from general adult population]
Intervention
Sotrovimab
Comparator
Standard care
Outcomes

PICO 4.1

Population
Children and adolescents under 16 years with mild or moderate covid-19 [adapted from general adult population]
Intervention
Casirivimab plus imdevimab
Comparator
Standard care
Outcomes

PICO 4.1

Population
Children and adolescents below 16 years with covid-19 [adapted from general adult population]
Intervention
Tocilizumab
Comparator
Standard care
Outcomes

PICO 4.1

Population
Children and adolescents with covid-19 [adapted from general adult population]
Intervention
Sarilumab
Comparator
Standard care
Outcomes

PICO 4.1

Population
Children and adolescents below 16 years with covid-19 [adapted from general adult population]
Intervention
Baricitinib
Comparator
Standard care
Outcomes